ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 114 filers reported holding ACCELERON PHARMA INC in Q4 2014. The put-call ratio across all filers is 0.52 and the average weighting 1.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $2,950,000 | +5.4% | 69,503 | -7.3% | 1.52% | -20.7% |
Q3 2017 | $2,799,000 | +11.0% | 74,990 | -9.6% | 1.92% | +39.5% |
Q2 2017 | $2,522,000 | +2.5% | 82,990 | -10.8% | 1.38% | +11.1% |
Q1 2017 | $2,461,000 | +3.7% | 92,990 | 0.0% | 1.24% | -20.4% |
Q4 2016 | $2,373,000 | +96.6% | 92,990 | +178.9% | 1.56% | +156.9% |
Q3 2016 | $1,207,000 | +5.8% | 33,340 | 0.0% | 0.61% | +9.8% |
Q2 2016 | $1,141,000 | +15.6% | 33,340 | -10.9% | 0.55% | +17.4% |
Q1 2016 | $987,000 | -51.7% | 37,404 | -10.7% | 0.47% | -47.8% |
Q4 2015 | $2,043,000 | +93.3% | 41,892 | -1.3% | 0.90% | +72.7% |
Q3 2015 | $1,057,000 | -21.4% | 42,463 | 0.0% | 0.52% | +2.6% |
Q2 2015 | $1,344,000 | +55.9% | 42,463 | +87.5% | 0.51% | +29.3% |
Q1 2015 | $862,000 | -48.0% | 22,647 | -46.8% | 0.39% | -37.6% |
Q4 2014 | $1,658,000 | +390.5% | 42,549 | +334.0% | 0.63% | +363.2% |
Q1 2014 | $338,000 | – | 9,805 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |